Company Overview - vTv Therapeutics (VTVT) is a biopharmaceutical company valued at $156 million, focusing on the discovery and development of orally administered small molecule drug candidates to address unmet medical needs [1] - The company is developing azeliragon TTP488 for Alzheimer's disease, currently in Phase 3 clinical trials, along with candidates for Type 1 and Type 2 diabetes, cancers, psoriasis, and COPD [1] Stock Performance - VTVT has experienced a significant surge of 182% over the past year, reaching a two-year high [4] - The stock recently traded at $41.35, with a 50-day moving average of $30.06, and has gained 51.55% in the last month [5] - Since the Trend Seeker issued a new "Buy" signal on December 8, the stock has increased by 35.86% [2] Technical Indicators - vTv Therapeutics scored a new two-year high of $41.49 on December 31 [3] - The company has a Weighted Alpha of +225.52 and a Relative Strength Index (RSI) of 77.02, indicating strong momentum [5] - Barchart gives vTv Therapeutics a 100% "Buy" opinion, with Wall Street leaning towards a "Strong Buy" rating and price targets reaching up to $47 [4][5]

Group 1 - Advanced Micro Devices, Inc. (AMD) shares increased significantly by 34.2% to $221.10 in pre-market trading following a major agreement with OpenAI to deploy up to 6 gigawatts of AMD Instinct GPU power for AI infrastructure [1][2] - The initial phase of the agreement includes a rollout of 1 gigawatt of AMD Instinct MI450 GPUs scheduled for the second half of 2026, with plans for further expansions across multiple generations of AMD's data center chips [1]